PLA2G10: Group 10 secretory phospholipase A2
Secretory calcium-dependent phospholipase A2 that primarily targets extracellular phospholipids.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on PLA2G10, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Varespladib methyl | Phase 3 | Anthera Pharmaceuticals | Small molecule | InhibitorGroup X secretory phospholipase A2 inhibitor | 0 |
- Neurodegenerative disease0.49
- Rheumatoid arthritis0.26
- Acute coronary syndrome0.15
- Hypertensive disorder0.14
- Response to xenobiotic stimulus0.14
- Myocardial infarction0.13
- Diabetes mellitus0.12
- Type 2 diabetes mellitus0.12
- Coronary artery disorder0.11
- Early-onset non-syndromic cataract0.10
- Early-onset zonular cataract0.09
- Early-onset posterior polar cataract0.09
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4342, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt O15496, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets